SG11202104657RA - Formulation of contrast media and process of preparation thereof - Google Patents

Formulation of contrast media and process of preparation thereof

Info

Publication number
SG11202104657RA
SG11202104657RA SG11202104657RA SG11202104657RA SG11202104657RA SG 11202104657R A SG11202104657R A SG 11202104657RA SG 11202104657R A SG11202104657R A SG 11202104657RA SG 11202104657R A SG11202104657R A SG 11202104657RA SG 11202104657R A SG11202104657R A SG 11202104657RA
Authority
SG
Singapore
Prior art keywords
formulation
preparation
contrast media
contrast
media
Prior art date
Application number
SG11202104657RA
Other languages
English (en)
Inventor
Stephan Holzschuh
Thomas Frenzel
Gregor Jost
Jessica Lohrke
Wolfgang Ebert
Thomas Brumby
Wolfgang Halfbrodt
Original Assignee
Bayer Ag
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, Bayer Pharma AG filed Critical Bayer Ag
Publication of SG11202104657RA publication Critical patent/SG11202104657RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A61K49/108—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA the metal complex being Gd-DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/124—Macromolecular compounds dendrimers, dendrons, hyperbranched compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes

Landscapes

  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
SG11202104657RA 2018-11-23 2019-11-21 Formulation of contrast media and process of preparation thereof SG11202104657RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18208090 2018-11-23
PCT/EP2019/082117 WO2020104602A1 (en) 2018-11-23 2019-11-21 Formulation of contrast media and process of preparation thereof

Publications (1)

Publication Number Publication Date
SG11202104657RA true SG11202104657RA (en) 2021-06-29

Family

ID=64456867

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202104657RA SG11202104657RA (en) 2018-11-23 2019-11-21 Formulation of contrast media and process of preparation thereof

Country Status (16)

Country Link
US (2) US11944690B2 (es)
EP (1) EP3883613A1 (es)
JP (2) JP7520007B2 (es)
KR (1) KR20210095168A (es)
CN (1) CN113164628A (es)
AU (1) AU2019382881A1 (es)
BR (1) BR112021007707A2 (es)
CA (1) CA3120665A1 (es)
CL (2) CL2021001331A1 (es)
CO (1) CO2021006034A2 (es)
IL (1) IL283281A (es)
JO (1) JOP20210114A1 (es)
MX (1) MX2021006024A (es)
PE (1) PE20211471A1 (es)
SG (1) SG11202104657RA (es)
WO (1) WO2020104602A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4335461A1 (en) * 2022-09-09 2024-03-13 Bayer AG Combinations of contrast agents
EP4360660A1 (en) * 2022-10-24 2024-05-01 Bayer AG Process for the preparation of a gadolinium contrast agent

Family Cites Families (177)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5560903A (en) 1981-07-24 1996-10-01 Schering Aktiengesellschaft Method of enhancing paramagnetism in chelates for MRI
US4647447A (en) 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
US4485237A (en) 1983-03-08 1984-11-27 The United States Of America As Represented By The Secretary Of The Navy Insensitive polynitramine compound
DE3625417C2 (de) 1986-07-28 1998-10-08 Schering Ag Tetraazacyclododecan-Derivate
US5039512A (en) 1986-08-04 1991-08-13 Salutar, Inc. NMR imaging with paramagnetic polyvalent metal salts of poly-(acid-alkylene-amino)-alkanes
DE3640708C2 (de) 1986-11-28 1995-05-18 Schering Ag Verbesserte metallhaltige Pharmazeutika
DE3728525A1 (de) 1987-08-24 1989-03-16 Schering Ag Mehrkernige substituierte komplexbildner, komplexe und komplexsalze, verfahren zu deren herstellung und diese enthaltende pharmazeutische mittel
US5284647A (en) 1988-03-18 1994-02-08 Schering Aktiengesellschaft Mesotetraphenylporphyrin complex compounds, process for their production and pharmaceutical agents containing them
US5334371A (en) 1988-07-20 1994-08-02 Schering Aktiengesellschaft Marcocyclic polyaza bicyclo compounds containing 5 or 6 membered rings, and method for MRI
DE4001655A1 (de) 1990-01-18 1991-07-25 Schering Ag 6-ring enthaltende makrocyclische tetraaza-verbindungen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
US5138923A (en) 1988-11-18 1992-08-18 Atlas Die, Inc. Rotary die cutter
US5011925A (en) 1989-03-09 1991-04-30 Mallinckrodt, Inc. Morpholinoamido EDTA derivatives
ATE173336T1 (de) 1989-08-28 1998-11-15 Gen Hospital Corp Hydroxy-aryl metallchelate für bildformung zur nmr diagnose
SG49726A1 (en) 1989-10-23 1998-06-15 Nycomed Salutar Inc Compounds
GB8923843D0 (en) 1989-10-23 1989-12-13 Salutar Inc Compounds
GB9320277D0 (en) 1993-10-01 1993-11-17 Nycomed Salutar Inc Chelants
US5650133A (en) 1990-01-19 1997-07-22 Nycomed Salutar Macrocyclic polyaza dichelates linked through ring nitrogens via an amide or ester functionality
US5679810A (en) 1990-01-19 1997-10-21 Salutar, Inc. Linear oligomeric polychelant compounds
CA2039399C (en) 1990-04-25 2000-09-05 C. Allen Chang Dual functioning excipient for metal chelate contrast agents
US7385041B2 (en) 1990-04-25 2008-06-10 Bracco International B.V. Dual functioning excipient for metal chelate contrast agents
US5141740A (en) 1990-11-21 1992-08-25 Mallinckrodt Medical, Inc. Complexes and compositions for magnetic resonance imaging and usage methods
CA2096543A1 (en) 1990-11-21 1992-05-22 Raghavan Rajagopalan Alkoxyamide derivatized chelates for mri
US5167942A (en) 1990-11-21 1992-12-01 Board Of Regents, The University Of Texas System Methods for the preparation of molecular sieves, including zeolites, using metal chelate complexes
EP0584256B1 (en) 1991-04-22 1999-11-10 Mallinckrodt Medical, Inc. Compounds and pharmaceutical compositions for detecting and localizing tissues having neurokinine 1 receptors
WO1992021017A1 (en) 1991-05-23 1992-11-26 Unger Evan C Liposoluble compounds for magnetic resonance imaging
US6875864B2 (en) 1991-08-01 2005-04-05 Bracco International B.V. Aminocarboxylate ligands having substituted aromatic amide moieties
CA2124329C (en) 1991-11-27 2008-11-18 Gregory A. Kopia Compounds, compositions and methods for binding bio-affecting substances to surface membranes of bio-particles
HUT67602A (en) 1991-12-10 1995-04-28 Dow Chemical Co Process for producing bicyclo-polyaza-macrocyclo-carboxylic acid complexes, their conjugates and contrast materials containing them
US5324503A (en) 1992-02-06 1994-06-28 Mallinckrodt Medical, Inc. Iodo-phenylated chelates for x-ray contrast
DE4232925A1 (de) 1992-09-28 1994-03-31 Diagnostikforschung Inst 3-,8-substituierte Deuteroporphyrinderivate, diese enthaltende pharmazeutische Mittel und Verfahren zu ihrer Herstellung
JPH08510458A (ja) 1993-06-02 1996-11-05 ブラッコ エッセ．ピ．ア． 沃素化された常磁性キレートおよびそれらの造影剤としての使用法
IT1264690B1 (it) 1993-07-08 1996-10-04 Bracco Spa Compositi oligomeri iodurati e composizioni diagnostiche contenenti gli stessi
AU1694895A (en) 1994-01-28 1995-08-15 Mallinckrodt Medical, Inc. Functionalized aza-bimacrocyclic ligands for imaging applications
US6693190B1 (en) 1994-05-11 2004-02-17 Bracco International B.V. Enhanced relaxivity monomeric and multimeric compounds
DE4425857A1 (de) 1994-07-07 1996-01-11 Schering Ag Kaskaden-Polymer-Komplexe, Verfahren zur ihrer Herstellung und diese enthaltende pharmazeutische Mittel
US5863518A (en) 1994-10-21 1999-01-26 Nihon Medi-Physics Co., Ltd. Diagnostic imaging agent with backbone with modified sugar chain end
US5672335A (en) 1994-11-30 1997-09-30 Schering Aktiengesellschaft Use of metal complexes as liver and gallbladder X-ray diagnostic agents
US5707605A (en) 1995-06-02 1998-01-13 Research Corporation Technologies Magnetic resonance imaging agents for the detection of physiological agents
DE19525924A1 (de) 1995-07-04 1997-01-09 Schering Ag Kaskaden-Polymer-Komplexe, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Mittel
US5739313A (en) 1995-11-13 1998-04-14 Regents Of The University Of Minnesota Radionuclide labeling of vitamin B12 and coenzymes thereof
DE19549286A1 (de) 1995-12-22 1997-06-26 Schering Ag Kaskaden-Polymer-Komplexe, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Mittel
DE19603033A1 (de) 1996-01-19 1997-07-24 Schering Ag Perfluoralkylhaltige Metallkomplexe, Verfahren zu deren Herstellung und ihre Verwendung in der NMR-Diagnostik
DE19608278A1 (de) 1996-02-23 1997-08-28 Schering Ag Pharmazeutische Mittel enthaltend perfluoralkylhaltige Metallkomplexe, und ihre Verwendung in der Tumortherapie und interventioniellen Radiologie
IT1283218B1 (it) 1996-03-08 1998-04-16 Bracco Spa Polichelanti, loro complessi con ioni metallici, loro preparazione e loro usi
US5866562A (en) 1996-10-25 1999-02-02 Bayer Aktiengesellschaft Ring-bridged bis-quinolines
US6045776A (en) 1996-12-04 2000-04-04 Schering Aktiengesellschaft Process for the production of metal-complex carboxylic acid amides
DE19652386A1 (de) 1996-12-04 1998-06-10 Schering Ag Verfahren zur Herstellung von Metallkomplexcarbonsäureamiden
US5919433A (en) 1996-12-04 1999-07-06 Schering Aktiengesellschaft Macrocyclic metal complex carboxylic acids, their use as well as process for their production
DE19652387A1 (de) 1996-12-04 1998-06-10 Schering Ag Macrocyclische Metallkomplexcarbonsäuren, ihre Verwendung sowie Verfahren zu ihrer Herstellung
DE19729013A1 (de) 1997-07-03 1999-02-04 Schering Ag Oligomere, perfluoralkylhaltige Verbindungen, Verfahren zu deren Herstellung und ihre Verwendung in der NMR-Diagnostik
US6019959A (en) 1997-07-31 2000-02-01 Schering Aktiengesellschaft Oligomeric compounds that contain perfluoroalkyl, process for their production, and their use in NMR diagnosis
DE19744003B4 (de) 1997-09-26 2004-07-08 Schering Ag Kontrastmittel für das Infarkt- und Nekroseimaging
AU750686B2 (en) 1997-10-27 2002-07-25 Research Corporation Technologies, Inc. Magnetic resonance imaging agents for the delivery of therapeutic agents
US6537520B1 (en) 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
DE19831217A1 (de) 1998-07-03 2000-01-05 Schering Ag Neue Porphyrinderivate, diese enthaltende pharmazeutische Mittel und ihre Verwendung in der photodynamischen Therapie und MRI-Diagnostik
EP0998946A1 (en) 1998-08-14 2000-05-10 K.U. Leuven Research & Development Non-porphyrin compound for use as a diagnosticum and/or pharmaceutical
US6056939A (en) 1998-08-28 2000-05-02 Desreux; Jean F. Self-assembling heteropolymetallic chelates as imaging agents and radiopharmaceuticals
US6511649B1 (en) 1998-12-18 2003-01-28 Thomas D. Harris Vitronectin receptor antagonist pharmaceuticals
FR2794744B1 (fr) 1999-06-09 2001-09-21 Guerbet Sa Complexes metalliques de polyaminoacides bicycliques, leur procede de preparation et leur application en imagerie medicale
US6221476B1 (en) 1999-06-11 2001-04-24 Ibc Advanced Technologies, Inc. Polymeric membranes functionalized with polyhydroxypyridinone ligands
US6232265B1 (en) 1999-06-11 2001-05-15 Ibc Advanced Technologies, Inc. Particulate solid supports functionalized with polyhydroxypyridinone ligands
DE19930177B4 (de) 1999-06-30 2007-02-08 Nikolai Vladimirovich Bovin Intermolekular assoziierende Verbindungen und deren Verwendung
DE19948651B4 (de) 1999-09-29 2006-10-05 Schering Ag Para- und diamagnetische perfluorhaltige Verbindungen enthaltende galenische Formulierungen, deren Herstellung und Verwendung
EP1088559A3 (de) 1999-09-29 2002-10-02 INSTITUT FÜR DIAGNOSTIKFORSCHUNG GmbH AN DER FREIEN UNIVERSITÄT BERLIN Galenische Formulierungen
DE10002939C1 (de) 2000-01-13 2001-09-20 Schering Ag Paramagnetische DOTA-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung für die Herstellung von pharmazeutischen Mitteln
AU2001231090A1 (en) 2000-01-22 2001-07-31 Epix Medical, Inc. Magnetic resonance imaging using contrast agents bioactivated by enzymatic cleavage
US20020052354A1 (en) 2000-01-27 2002-05-02 Schering Ag Paramagnetic DOTA derivatives, pharmaceutical agents that contain the latter, process for their production, and their use for MR imaging of necrosis and infarction
IT1317862B1 (it) 2000-02-29 2003-07-15 Bracco Spa Coniugati di acidi biliari con chelati complessi di ioni metallici eloro uso.
JP2005538030A (ja) 2000-06-21 2005-12-15 デュポン ファーマシューティカルズ カンパニー 組み合わせ療法での使用のための血管新生障害の画像診断用医薬
EP1307226B1 (en) 2000-06-21 2008-11-19 Lantheus Medical Imaging, Inc. Vitronectin receptor antagonist pharmaceuticals
DE10066210B4 (de) 2000-08-11 2008-02-28 Bayer Schering Pharma Ag Verwendung von perfluoralkylhaltigen Metallkomplexen als Kontrastmittel im MR-Imaging zur Darstellung von Plaques
DE10040381C1 (de) 2000-08-11 2002-06-06 Schering Ag Perfluoralkylhaltige Komplexe mit Zuckerresten, Verfahren zu deren Herstellung und ihre Verwendung
DE10040858C2 (de) 2000-08-11 2003-12-18 Schering Ag Perfluoralkylhaltige Komplexe mit polaren Resten, Verfahren zu deren Herstellung und ihre Verwendung
IL145723A0 (en) 2000-10-11 2002-07-25 Nihon Mediphysics Co Ltd Process for producing an amide compound
US20030050452A1 (en) 2000-12-26 2003-03-13 Yuji Hashiguchi Process for producing metal complex of aminooligosaccharide derivative
US20030004236A1 (en) 2001-04-20 2003-01-02 Meade Thomas J. Magnetic resonance imaging agents for detection and delivery of therapeutic agents and detection of physiological substances
DE10135355C1 (de) 2001-07-20 2003-04-17 Schering Ag Konjugate makrocyclischer Metallkomplexe mit Biomolekülen und deren Verwendung zur Herstellung von Mitteln für die NMR- und Radiodiagnostik sowie die Radiotherapie
DE10135356C1 (de) 2001-07-20 2003-04-17 Schering Ag Makrocyclische Metallkomplexe und deren Verwendung zur Herstellung von Konjugaten mit Biomolekülen
TWI240632B (en) 2001-07-30 2005-10-01 Epix Medical Inc Purified peptides for peptide-based multimeric targeted contrast agents
ITMI20011708A1 (it) 2001-08-03 2003-02-03 Bracco Imaging Spa Coniugati di peptidi, loro derivati con complessi metallici e utilizzo per i'indagine diagnostica tramite imaging per risonanza magnetica(m
FR2836916B1 (fr) 2002-03-05 2004-06-11 Guerbet Sa Oligomeres de chelates de gadolinium, leur application comme produits de contraste en imagerie par resonance magnetique et leurs intermediaires de synthese
US20030198597A1 (en) 2002-04-22 2003-10-23 Meade Thomas J. Novel macrocyclic activatible magnetic resonance imaging contrast agents
DE10231799B4 (de) 2002-07-10 2006-10-05 Schering Ag Verwendung von perfluoralkylhaltigen Metallkomplexen als Kontrastmittel im MR-Imaging zur Darstellung von Intravasalen Thromben
US7226577B2 (en) 2003-01-13 2007-06-05 Bracco Imaging, S. P. A. Gastrin releasing peptide compounds
DE10307759B3 (de) 2003-02-19 2004-11-18 Schering Ag Trimere makrocyclisch substituierte Benzolderivate, deren Herstellung und Verwendung als Kontrastmittel sowie diese enthaltende pharmazeutische Mittel
WO2005001415A2 (en) 2003-05-23 2005-01-06 Epix Pharmaceuticals, Inc. Optically pure and enriched isomers of chelating ligands and contrast agents
AR047692A1 (es) 2003-07-10 2006-02-08 Epix Medical Inc Imagenes de blancos estacionarios
DE102004023093B3 (de) 2004-05-05 2006-03-02 Schering Ag Trimere makrocyclisch substituierte Halogen-Benzolderivate
DE102004026103A1 (de) 2004-05-25 2005-12-22 Schering Ag Trimere makrocyclisch substituierte Aminoisophthalsäure-Halogen-Benzolderivate
ATE430146T1 (de) 2004-07-02 2009-05-15 Bracco Imaging Spa Kontrastmittel mit hoher relaxivität zur verwendung in der magnetresonanzbilddarstellung (mri), enthaltend eine chelatbildende gruppe mit polyhydroxylierten substituenten
US8153784B2 (en) 2004-07-07 2012-04-10 The General Hospital Corporation Imaging of enzyme activity
US20060057071A1 (en) 2004-09-14 2006-03-16 Wing-Tak Wong Paramagnetic complexes with pendant crown compounds showing improved targeting-specificity as MRI contrast agents
US7205385B2 (en) 2004-11-12 2007-04-17 General Electric Company Polymerization method for the synthesis of polypeptide imaging agents
EP1848466A4 (en) 2005-01-31 2012-11-21 Yeda Res & Dev MRI CONTRAST AGENTS FOR DIAGNOSIS AND PROGNOSIS OF TUMORS
GB0512751D0 (en) 2005-06-22 2005-07-27 Glaxo Group Ltd New adjuvant
FR2891830B1 (fr) 2005-10-07 2011-06-24 Guerbet Sa Composes a chaines aminoalcools courtes et complexes metalliques pour l'imagerie medicale
WO2007064226A2 (en) 2005-12-01 2007-06-07 Ge Healthcare As Method of dynamic nuclear polarisation (dnp) using a trityl radical and a paramagnetic metal ion
US20090238768A1 (en) 2005-12-02 2009-09-24 Oskar Axelsson Multimeric magnetic resonance contrast agents
ES2393750T3 (es) 2005-12-16 2012-12-27 Ge Healthcare As Procedimiento para producir carbosilatos hiperpolarizados de aminas orgánicas
US20070293656A1 (en) 2005-12-29 2007-12-20 Epix Pharmaceuticals, Inc. Collagen binding peptides
US20070202047A1 (en) 2006-01-05 2007-08-30 Markus Wolf Polyamine-substituted ligands for use as contrast agents
EP1815870A1 (en) 2006-02-01 2007-08-08 DKFZ Deutsches Krebsforschungszentrum Cyanine dye compounds linked to metal chelator for bi-modal diagnostic imaging
KR20080099279A (ko) 2006-02-24 2008-11-12 말린크로트, 인코포레이티드 이관능성 레조르시놀, 티오레조르시놀, 및 디티오레조르시놀 유도체 금속 킬레이팅 컨쥬게이트
WO2007112100A2 (en) 2006-03-24 2007-10-04 The University Of Utah Research Foundation Highly fluorinated oils and surfactants and methods of making and using same
WO2007111514A1 (en) 2006-03-29 2007-10-04 Ge Healthcare As Contrast agents for magnetic resonance imaging and spectroscopy consisting of a cyclic oligoamid core of 3 to 4 identical monomer units with 3 to 4 paramagnetic chelate side chains
WO2007111515A2 (en) 2006-03-29 2007-10-04 Ge Healthcare As Method to produce hyperpolarised carboxylates and sulphonates
WO2007128873A1 (en) 2006-05-05 2007-11-15 Wallac Oy A method for the preparation of maleimido derivatives of biomolecule labeling reactants and conjugates derived thereof
DE102006021495A1 (de) 2006-05-09 2007-11-15 Bayer Schering Pharma Ag Verwendung von perfluoralkylhaltigen Metallkomplexen als Kontrastmittel zur Diagnose der Alzheimer Krankheit
JP2008012596A (ja) 2006-07-03 2008-01-24 Aji Kk 把持装置
EP2076557A4 (en) 2006-08-11 2012-08-29 Starpharma Pty Ltd POLYLYSINE DENDRIMER CONTRAST AGENT
KR101336505B1 (ko) 2006-08-17 2013-12-05 에픽스 파마슈티칼스, 인코포레이티드 림프계의 영상화 방법
DE102007002726A1 (de) 2007-01-18 2008-07-31 Bayer Schering Pharma Aktiengesellschaft Neue Kaskaden-Polymer-Komplexe, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Mittel
EP1980251A1 (en) 2007-04-13 2008-10-15 Glaxo Group Limited Pyrrolo[3,2,1-ij]quinoline-4-one derivatives for treating tuberculosis
CN101970014A (zh) 2007-07-26 2011-02-09 通用电气医疗集团英国有限公司 包含超极化的13c-乳酸盐的成像介质及其用途
US20110250138A1 (en) 2007-08-01 2011-10-13 Alnylam Pharmaceuticals, Inc. Single-stranded and double-stranded oligonucleotides comprising a metal-chelating ligand
EP2180902B1 (en) 2007-08-27 2011-11-23 GE Healthcare Limited Imaging medium comprising hyperpolarised ¹³c-acetate and use thereof
CN101796413B (zh) 2007-09-07 2014-08-20 通用电气健康护理有限公司 测定pdh活性的方法和用于该方法中的成像介质
FR2921929B1 (fr) 2007-10-08 2013-01-11 Commissariat Energie Atomique Procede de preparation de materiaux polymeriques dopes par des elements metalliques et materiaux obtenus par ce procede
DE102007058220A1 (de) 2007-12-03 2009-06-04 Bayer Schering Pharma Aktiengesellschaft Dimere macrocyclisch substituierte Benzolderivate
EP2902041A1 (en) 2007-12-19 2015-08-05 GE Healthcare Limited Composition and method for generating a metabolic profile using 13C-MR detection
US20110038804A1 (en) 2007-12-21 2011-02-17 Anna Gisselsson Mr imaging agent, imaging medium and methods of imaging wherein such an imaging medium is used
GB0801199D0 (en) 2008-01-23 2008-02-27 Acal Energy Ltd Fuel cells
US8545813B2 (en) 2008-01-25 2013-10-01 Northwestern University Pre-templated macromolecular architectures with multiple Gd(III) complexes and methods of use as MRI contrast agents
WO2009098192A1 (en) 2008-02-04 2009-08-13 Ge Healthcare Limited Mr imaging agent or medium compressing hzperpolarised 13c alanine and methods of imaging wherein such an imaging medium is used
WO2009098191A2 (en) 2008-02-04 2009-08-13 Ge Healthcare Limited Method to produce hyperpolarised amino acids and aminosulphonic acids
US20090208421A1 (en) 2008-02-19 2009-08-20 Dominique Meyer Process for preparing a pharmaceutical formulation of contrast agents
US20110038805A1 (en) 2008-04-18 2011-02-17 Andreas Meijer Compounds comprising paramagnetic chelates arranged around a central core and their use in magneto resonance imaging and spectroscopy
CN102076214A (zh) 2008-05-19 2011-05-25 伯拉考成像股份公司 释放胃泌素的肽化合物
EP2149567A1 (en) 2008-07-18 2010-02-03 Bayer Schering Pharma Aktiengesellschaft Cyclic polyamines for binding phosphatidylserine
WO2010039609A2 (en) 2008-09-30 2010-04-08 Mallinckrodt Inc. A version of fdg detectable by single-photon emission computed tomography
US20110217241A1 (en) 2008-11-14 2011-09-08 University Of Maryland, Baltimore Conjugates of 19f mr imaging tracers for use in multi-chromic mri imaging
FR2939318B1 (fr) 2008-12-10 2012-07-13 Guerbet Sa Systeme d'encapsulation pour imagerie cest avec quelate q superieur ou egal a 2
US9056841B2 (en) 2009-03-19 2015-06-16 The Johns Hopkins University PSMA-targeting compounds and uses thereof
WO2010147666A1 (en) 2009-06-19 2010-12-23 Memorial Sloan-Kettering Cancer Center Compounds useful as carbonic anhydrase modulators and uses thereof
WO2011031740A1 (en) 2009-09-09 2011-03-17 Achaogen, Inc. Antibacterial fluoroquinolone analogs
US20110081428A1 (en) 2009-09-16 2011-04-07 The Buck Institute For Age Research Use of thioflavin-like compounds to increase life span and/or health span
DE102009053171B4 (de) * 2009-11-04 2011-07-21 Bayer Schering Pharma Aktiengesellschaft, 13353 Verfahren zur Herstellung des Calcium-Komplexes von Dihydroxy-hydroxy-methylpropyl-tetraazacyclododecan-triessigsäure (Calcobutrol)
NO331773B1 (no) 2009-12-18 2012-03-26 Ge Healthcare As Mangankelater, sammensetninger omfattende slike og anvendelse av disse som kontrastmidler for magnettomografi (MR)
WO2011088193A2 (en) 2010-01-13 2011-07-21 University Of Medicine And Dentistry Of New Jersey Fluorophore chelated lanthanide luminiscent probes with improved quantum efficiency
JP5758982B2 (ja) 2010-04-08 2015-08-05 ブラッコ・イメージング・ソシエタ・ペル・アチオニＢｒａｃｃｏ Ｉｍａｇｉｎｇ Ｓ．Ｐ．Ａ． 過分極基質の製造方法およびｍｒｉのための方法
EP2397466B1 (en) 2010-06-15 2012-11-28 Centre National De La Recherche Scientifique CNRS X-ray and gamma-photon activatable organic compounds, their preparation and their uses
EP2457594A1 (en) 2010-11-05 2012-05-30 Bracco Imaging S.p.A Cest systems exhibiting a concentration independent responsiveness
US9011816B2 (en) 2011-03-25 2015-04-21 Case Western Reserve University Fibronectin targeting contrast agent
CN103547290A (zh) 2011-04-20 2014-01-29 Rf医疗公司 靶向造影剂及其用途
WO2012143355A1 (en) * 2011-04-21 2012-10-26 Bayer Intellectual Property Gmbh Preparation of high-purity gadobutrol
ES2732060T3 (es) 2011-08-05 2019-11-20 Molecular Insight Pharm Inc Inhibidores radiomarcados del antígeno de membrana específico de la próstata
CN102973955B (zh) 2011-09-06 2016-03-23 中国科学院福建物质结构研究所 一种含三价铝的磁共振成像造影剂
CN102442996B (zh) 2011-09-16 2014-09-24 中山大学附属第一医院 多胺类小分子显像剂、其生产方法及其应用
ES2414291B2 (es) 2011-12-16 2014-02-13 Universitat De Valencia Compuestos macrocíclicos de tipo escorpiando y su uso como antiparasitarios.
KR101336071B1 (ko) 2012-01-04 2013-12-05 한국원자력의학원 암 진단용 ｍｒｉ／ｃｔ 이중 조영제 및 그 제조방법
CN102614531B (zh) 2012-04-06 2013-06-05 中国科学院长春应用化学研究所 以二乙酰基苯或三乙酰基苯为连接体的多核非离子型磁共振成像造影剂
US9585975B2 (en) 2012-04-27 2017-03-07 Northwestern University MRI contrast agents
KR101456233B1 (ko) 2012-08-09 2014-11-04 한국원자력의학원 아미노시클로펜탄카르복실산-함유 시클로 ｒｇｄ 유도체, 그 제조방법 및 그것을 포함하는 ｍｒｉ 조영제
KR101456234B1 (ko) 2012-08-09 2014-11-04 한국원자력의학원 아미노시클로헥산카르복실산-함유 시클로 ｒｇｄ 유도체, 그 제조방법 및 그것을 포함하는 ｍｒｉ 조영제
WO2014052471A1 (en) 2012-09-25 2014-04-03 Biosynthema Inc. Grpr-antagonists for detection, diagnosis and treatment of grpr-positive cancer
US20150297761A1 (en) 2012-11-12 2015-10-22 The General Hospital Corporation Peptidic structures incorporating an amino acid metal complex and applications in magnetic resonance imaging
ES2648096T3 (es) 2013-01-14 2017-12-28 Molecular Insight Pharmaceuticals, Inc. Radiofármacos a base de triazina y agentes de radioformación de imágenes
CN105189521A (zh) 2013-02-12 2015-12-23 拜耳医药股份公司 结合至血小板特异性糖蛋白IIb/IIIa的金属螯合化合物
ES2626582T5 (es) 2013-04-26 2022-10-07 Guerbet Sa Formulación de producto de contraste y su procedimiento de preparación asociado
WO2014197763A1 (en) 2013-06-07 2014-12-11 The Board Of Regents Of The University Of Teas System Molecular design toward dual-modality probes for radioisotope-based imaging (pet or spect) and mri
CN103554185A (zh) 2013-07-04 2014-02-05 上海工程技术大学 一类大环多胺类多齿配体及其合成方法
EP2873679A1 (en) 2013-11-13 2015-05-20 F.Hoffmann-La Roche Ag Camelid single-domain antibody directed against amyloid bêta and methods for producing conjugates thereof
EP2873680A1 (en) 2013-11-13 2015-05-20 F.Hoffmann-La Roche Ag Oligopeptide and methods for producing conjugates thereof
CN103611171B (zh) 2013-11-25 2015-03-25 中国科学院长春应用化学研究所 以四苯酰基甲烷为连接体的非离子型多核磁共振成像造影剂及其制备方法
US10683272B2 (en) 2014-05-06 2020-06-16 The Johns Hopkins University Metal/radiometal-labeled PSMA inhibitors for PSMA-targeted imaging and radiotherapy
US11324827B2 (en) 2014-10-01 2022-05-10 Xiamen Sinopeg Biotech Co., Ltd. Multifunctionalized polyethylene glycol derivative and preparation method therefor
US20180221513A1 (en) 2015-03-16 2018-08-09 Northwestern University Contrast-agent-labeled peptide amphiphile nanofibers
EP3101012A1 (en) * 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft New gadolinium chelate compounds for use in magnetic resonance imaging
US20160375155A1 (en) 2015-06-29 2016-12-29 Collagen Medical, LLC Collagen Imaging Compositions
CA2995084C (en) 2015-08-17 2024-02-13 Southwestern Oklahoma State University Compositions comprising macrocycle derivatives incorporating bridged macrocycles and methods of producing and using same
US11110185B2 (en) 2015-11-30 2021-09-07 Ge Healthcare As Combination formulation
KR102703312B1 (ko) 2015-12-10 2024-09-05 브라코 이미징 에스.피.에이. 조영제
JP6896733B2 (ja) 2015-12-10 2021-06-30 ブラッコ・イメージング・ソシエタ・ペル・アチオニＢｒａｃｃｏ Ｉｍａｇｉｎｇ Ｓ．Ｐ．Ａ． 二量体造影剤
US10656229B2 (en) 2016-04-06 2020-05-19 Northwestern University Magnetic barcode imaging
EP3442949B1 (en) 2016-04-13 2022-06-08 Bracco Imaging S.p.A. Contrast agents
JP7034160B2 (ja) 2016-11-28 2022-03-11 バイエル・ファルマ・アクティエンゲゼルシャフト 磁気共鳴画像法に使用するための高緩和度ガドリニウムキレート化合物
JP7145156B2 (ja) 2016-12-12 2022-09-30 ブラッコ・イメージング・ソシエタ・ペル・アチオニ 二量体造影剤

Also Published As

Publication number Publication date
MX2021006024A (es) 2021-07-06
CL2021001331A1 (es) 2021-10-22
CN113164628A (zh) 2021-07-23
KR20210095168A (ko) 2021-07-30
JOP20210114A1 (ar) 2023-01-30
IL283281A (en) 2021-07-29
JP2024133090A (ja) 2024-10-01
BR112021007707A2 (pt) 2021-07-27
US20240252690A1 (en) 2024-08-01
US11944690B2 (en) 2024-04-02
CL2023003162A1 (es) 2024-04-01
CA3120665A1 (en) 2020-05-28
PE20211471A1 (es) 2021-08-05
WO2020104602A1 (en) 2020-05-28
CO2021006034A2 (es) 2021-05-20
JP2022508185A (ja) 2022-01-19
EP3883613A1 (en) 2021-09-29
US20220008562A1 (en) 2022-01-13
AU2019382881A1 (en) 2021-05-20
JP7520007B2 (ja) 2024-07-22

Similar Documents

Publication Publication Date Title
EP3576782A4 (en) COMPOSITIONS OF RECOMBINATION PRODUCT-PEPTIDE AND THEIR METHODS OF USE
HK1252030A1 (zh) 葡萄糖激酶激活劑的口服製劑及其製備方法
EP3437637A4 (en) PHARMACEUTICAL PREPARATION OF PALBOCICLIB AND MANUFACTURING METHOD THEREFOR
EP3682884A4 (en) CRYSTALLINE FORM OF GSK1278863 AND PROCESS OF PREPARATION AND ITS PHARMACEUTICAL USE
EP3749343A4 (en) FORMULATION AND METHOD OF USE
EP3416665A4 (en) FORMULATION AND METHOD OF USE
EP3426227A4 (en) COMPOSITION AND METHOD OF USING ORAL COLCHICIN LIQUID
EP3380525A4 (en) PHARMACEUTICAL FORMULATIONS AND METHODS OF USE
HK1246656A1 (zh) 含有伊立替康的口服固體製劑及其製備方法
EP3731833A4 (en) COMPOSITIONS CONTAINING THYMOHYDROQUINONE AND METHOD FOR MANUFACTURING THEREOF
IL266132B (en) Pharmaceutical formulations and methods for their preparation
SG11202009315WA (en) Formulation and method of preparation
ZA202003590B (en) Process for the preparation of opicapone and intermediates thereof
IL283281A (en) Formulation of contrast media and process for its preparation
EP3485886A4 (en) ORAL PHARMACEUTICAL COMPOSITION MADE FROM TECOVIRIMAT AND PRODUCTION METHOD THEREFOR
IL290185A (en) Crystalline forms of risdiplam and their preparation process
EP3619193A4 (en) AMINOARYL BENZAMIDE COMPOUNDS AND METHOD OF USING THEREOF
EP3572399A4 (en) CRYSTALLINE FORM OF GFT-505 AND METHOD OF PREPARING AND USING THE SAME
EP3525787A4 (en) TREATMENT METHODS AND PHARMACEUTICAL COMPOSITIONS USING BCN057 OR BCN512
EP3503885A4 (en) PHARMACEUTICAL COMPOSITION AND METHODS OF USE
EP3880183A4 (en) PHARMACEUTICAL PREPARATION OF FRUQUINTINIB AND ITS USE
EP3648777A4 (en) EXOSOMES AND METHOD OF USE THEREOF
EP3576761A4 (en) HERBO-MINERAL FORMULATION FOR THE TREATMENT OF CANCER AND RELATED PREPARATION PROCESS
EP3481181A4 (en) PROBIOTIC POULTRY VACCINE COMPOSITIONS AND METHOD FOR USE THEREOF
ZA202007107B (en) Compositions comprising pcsk9-binding molecules and methods of use